Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Human Metabolome Technologies's quarterly market cap
declined
from Sep. 2025 (円4,246 Mil) to Dec. 2025 (円3,714 Mil) but then
increased
from Dec. 2025 (円3,714 Mil) to Mar. 2026 (円3,800 Mil).
Human Metabolome Technologies's annual market cap
declined
from Jun. 2023 (円4,424 Mil) to Jun. 2024 (円3,739 Mil) but then
increased
from Jun. 2024 (円3,739 Mil) to Jun. 2025 (円4,360 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Human Metabolome Technologies's Enterprise Value for Today is 円2,155 Mil.
Human Metabolome Technologies (TSE:6090) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Human Metabolome Technologies Market Cap Related Terms
Human Metabolome Technologies Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Human Metabolome Technologies's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Human Metabolome Technologies Market Cap vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Human Metabolome Technologies's Market Cap distribution charts can be found below:
* The bar in red indicates where Human Metabolome Technologies's Market Cap falls into.
Human Metabolome Technologies Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Human Metabolome Technologies (TSE:6090) has a Market Cap of 円3,496 Mil as of Aug. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Human Metabolome Technologies and its competitors. According to the industry distribution chart, Human Metabolome Technologies ranks #150 out of 216 companies in the Medical Diagnostics & Research industry, placing it in the top 69.4%.
Is Human Metabolome Technologies' Market Cap too high?
Human Metabolome Technologies' current Market Cap is 円3,496 Mil. Based on the distribution chart, Human Metabolome Technologies ranks #150 out of 216 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Human Metabolome Technologies has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Human Metabolome Technologies' Market Cap compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Human Metabolome Technologies ranks #150 out of 216 companies for Market Cap. This places Human Metabolome Technologies in the lower half of its industry. The industry median Market Cap is 63.27. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Diagnostics & Research company?
The median Market Cap among Medical Diagnostics & Research companies is 63.27, based on 216 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Human Metabolome Technologies and its competitors. For the Medical Diagnostics & Research industry, the median Market Cap is 63.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Human Metabolome Technologies's current Market Cap is 円3,496 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Human Metabolome Technologies stock overvalued right now?
Based on GuruFocus' analysis, Human Metabolome Technologies (TSE:6090) is currently considered Fairly Valued. The stock's GF Value™ is 円693.69, compared to a current price of 円645.00 — trading 7% below its estimated fair value. The current Market Cap is 円3,496 Mil. Human Metabolome Technologies' overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Human Metabolome Technologies (TSE:6090), the current Market Cap is 円3,496 Mil as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Human Metabolome Technologies (TSE:6090) Overvalued in 2026?
Based on GuruFocus' analysis, Human Metabolome Technologies stock appears to be undervalued.
The current stock price of 円645.00 is trading 7% below its estimated GF Value™ of 円693.69.
GuruFocus considers Human Metabolome Technologies to be Fairly Valued.
Key valuation signals for TSE:6090:
Market Cap: 円3,496 Mil
GF Value™: 円693.69 vs. price of 円645.00 (7% below fair value)
No single metric tells the full story. See the TSE:6090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:6090 has been successfully added to your 
